Form 8-K

8-K — PDS Biotechnology Corp

Accession: 0001140361-26-035809

Filed: 2026-09-04

Period: 2026-08-31

CIK: 0001472091

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Financial Statements and Exhibits

Documents

8-K — ef20081442_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (ef20081442_ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20081442_8k.htm · Sequence: 1

false0001472091NASDAQ00014720912026-08-312026-08-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2026

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware

001-37568

26-4231384

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

303A College Road East,

Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

Registered

Common Stock, par value $0.00033 per share

PDSB

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 1.01

Entry into a Material Definitive Agreement.

On August 31, 2026, PDS Biotechnology Corporation, a Delaware corporation (the “Company”), entered into a First Amendment to

Promissory Note (the “Amendment”) with YA II PN, Ltd. (the “Holder”), which amends that certain Promissory Note made by the Company in favor of the Holder, issued as of June 15, 2026, in the original principal amount of $6,000,000 (the “Note”). The

Amendment made the following modifications to the Note: (i) Section 1(f) of the Note was amended and restated in its entirety to, among other things, require the Company to deliver weekly remittance notices to the Holder setting forth net proceeds

received from sales under the Company’s at-the-market offering program during the prior week and to pay the applicable portion of such net Proceeds within one (1) business day after delivery of such notice; (ii) the cure period for a Nasdaq listing

deficiency under Section 1(g) of the Note was extended from seventy-five (75) days to one-hundred eighty (180) days; and (iii) a new Section 1(i) was added to the Note requiring that 100% of net cash proceeds received from any equity or equity-linked

financing (outside of the Company’s at-the-market offering) be applied as a mandatory deemed redemption payable to the Holder within five (5) business days of receipt. The Amendment becomes effective upon execution and delivery by each party and the

Company having paid in full the installment amount due on the September 14, 2026, pursuant to the terms of the Note.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full

text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

10.1

First Amendment to Promissory Note, dated as of August 31, 2026, by and between PDS Biotechnology Corporation and YA II PN, Ltd.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

PDS BIOTECHNOLOGY CORPORATION

Date: September 4, 2026

By: /s/ Frank Bedu-Addo, Ph.D.

Name: Frank Bedu-Addo, Ph.D.

Title: President and Chief Executive Officer

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: ef20081442_ex10-1.htm · Sequence: 2

Exhibit 10.1

FIRST AMENDMENT TO PROMISSORY NOTE

This First Amendment to Promissory Note (this “Agreement”) is made as of

August 31, 2026, by and between PDS BIOTECHNOLOGY CORPORATION, a Delaware corporation (the “Company”),

and YA II PN, LTD. (“Holder”).

RECITALS

A. The Company and Holder are parties to that certain

Promissory Note made by the Company in favor Holder, issued as of June 15, 2026 (as amended, supplemented or otherwise modified from time to time, the “Note”). Capitalized

terms used herein without definition shall have the meanings ascribed to such terms in the Note.

B. The Company has requested that Holder make certain

amendments to the Note as more fully described herein and, subject to the express terms and conditions set forth herein, Holder has agreed to Company’s requests.

NOW, THEREFORE, in consideration of the foregoing premises

and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each party hereto, the parties hereby agree as follows:

1. Amendments.

(a) Section 1(f) of the Note is hereby amended and restated in its entirety as follows:

“(f) ATM Proceeds. All net cash proceeds received from sales of Common Shares pursuant to the ATM after the Issuance Date (“Net Proceeds”)

shall be applied by the Company to the payment of the Installment Principal Amount (including any increased amortization pursuant to Section (1)(e) above, as it may be decreased under Section 1(d), Section 1(i) and the last sentence of this Section

(1)(f)) due on the next Installment Date (such Installment Date, the “Next Installment Date”) and accrued and unpaid interest thereon to the date of such payment, until

such Net Proceeds equal the sum of such Installment Principal Amount and accrued and unpaid interest thereon to the date of prepayment. If the amount of Net Proceeds received after the immediately preceding Installment Date (or after the Issuance

Date, as applicable) and prior to the Next Installment Date exceeds 100% of the sum of the Installment Principal Amount due on the Next Installment Date (as it may be reduced under Section (1)(d), Section 1(i) and this Section (1)(f)) and accrued

and unpaid interest thereon to the date of prepayment, after payment of the Installment Principal Amount due on the Next Installment Date and accrued and unpaid interest thereon through the date of prepayment, 40% of the Net Proceeds may be

retained by the Company and 60% of the Net Proceeds shall be paid by the Company to the Holder and applied to the following monthly Installment Principal Amounts and accrued and unpaid interest thereon to the date of prepayment, in inverse

chronological order. Notwithstanding the foregoing payment timing provisions, the Company shall deliver to the Holder, on a weekly basis (provided Net Proceeds have been received in such prior week), a notice setting forth the aggregate amount of

Net Proceeds received by the Company during the prior week, and the Company shall pay the applicable portion of such Net Proceeds to the Holder within one (1) Business Day of delivery of such remittance notice (with such payments applied in

accordance with this Section 1(f), including the 60/40 allocation for any Net Proceeds in excess of 100% of the Installment Principal Amount and accrued interest due on the Next Installment Date), and interest shall cease to accrue on such paid

amounts of Principal as of the date of such payment.”

(b) Section 1(g) of the Note is hereby amended by deleting the reference to “seventy-five (75)” contained therein and replacing it with “one-hundred eighty (180)”.

following new Section 1(i) immediately after Section 1(h) of the Note:

“(i) Non-ATM Offering Proceeds. If, on or after the Issuance Date, the Company receives cash proceeds from sales of Common

Shares pursuant to an equity or equity linked financing for bona fide capital raising purposes outside of the ATM (“Non-ATM Offering”), then upon receipt of any such net cash proceeds the Company shall be deemed to have delivered to the Holder a Redemption Notice as of the closing date of such Non-ATM Offering with a

Redemption Amount equal to 100% of the amount of such net cash proceeds received from the Non-ATM Offering, and such Redemption Amount shall paid to the Holder within five (5) Business Days of receipt of such net proceeds. Upon receipt by the

Holder, such net proceeds shall be applied to the payment of (i) all accrued and unpaid interest outstanding as of the date of such deemed Redemption Notice, and then (ii) towards the outstanding Principal balance of this Note. If such redemption is a Redemption in Part, then the amounts paid shall be applied to future monthly Installment Amounts in reverse chronological order.”i

2. Limitations; No Waivers. The Company acknowledges and agrees that: (i) Holder does not waive or agree to forbear with respect to, any failure by the Company to perform its

obligations under the Note or with respect to any Event of Default, and Holder does not forbear with respect to any Event of Default, (ii) the execution, delivery, and performance of this Agreement shall not operate as a waiver of, or as an

amendment of, any right, remedy, power or privilege of Holder under the Note as in effect on or prior to the date hereof; and (iii) Holder has not waived any Events of Default or any of its rights or remedies with respect thereto.

3. Conditions Precedent. This Agreement shall become effective on the date when Holder shall have received this Agreement

duly executed and delivered by each of the Company and Holder and the Company having paid in full the Installment Amount due on the September 14, 2026 Installment Date.

4. Ratification and Affirmation of Note. The Company hereby ratifies and affirms the Note and acknowledges that, except as specifically amended by this Agreement, the Note is,

and shall remain, unchanged and in full force and effect in all respects. The Company agrees that the Note constitutes a valid and binding obligation and agreement of the Company enforceable by Holder against the Company in accordance with their

terms. Upon the effectiveness of this Agreement, each reference in the Note to “this Agreement”, “hereunder”, “hereof”, “herein”, or words of like import shall mean and be a reference to the Note as amended by this Agreement, and each reference to

the Note in any other document, instrument or agreement executed and/or delivered in connection with the Note shall mean and be a reference to the Note as amended by this Agreement.

5. Miscellaneous.

(a) Strict Compliance. Notwithstanding any prior conduct of Holder, Holder hereby demands strict compliance with the terms, provisions, and conditions of the Note.

(b) Governing Law. Section 8 of the Note shall apply herein

as if fully set forth herein, mutatis mutandis.

(c) General Acknowledgements. The Company acknowledges and agrees that neither this Agreement nor any other agreement entered into in connection herewith or pursuant to the terms hereof shall be deemed or construed to be a

satisfaction, reinstatement, accord and satisfaction, novation or release of any amount owed to Holder pursuant to the Note, or any rights or obligations under the Note, or a waiver by Holder of any of its rights under the Note, at law or in

equity.

(d) Communications and Notices. All notices, demands or other communications to be given or delivered by reason of the provisions of this Agreement shall be given in accordance with Section 5 of the Note.

(e) Time of Essence. Time is of the essence of this Agreement.

(f) Tax Consequences. This Agreement is enforceable regardless of its tax consequences. No party makes any representations with respect to any tax consequences in connection with entry into this Agreement or any payments

required hereunder.

(g) Binding Effect. This Agreement and all rights and powers granted hereby will bind and inure to the benefit of the parties hereto and their respective permitted successors and assigns.

(h) Severability. In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or

obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

(i) No Third-Party Beneficiaries. Except as expressly set forth herein, the rights and benefits of this Agreement shall not inure to the benefit of any third party.

(j) Modifications. No modification of this Agreement shall be binding or enforceable unless in writing and signed by or on behalf of the party against whom enforcement is sought.

(k) Headings. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement.

(l) Counterparts. This Agreement may be executed in counterparts, each of equal import, which, when joined, shall constitute one document. Signatures may be delivered by electronic transmission and such signatures shall be

treated as originals thereof. Any electronic copy of this Agreement, or of any counterpart, shall be deemed to be the equivalent of an original.

(m) Entire Agreement/Further Assurances. This Agreement constitutes the entire agreement among the parties concerning the subject matter set forth herein and supersedes any and all prior and contemporaneous agreements,

negotiations, understandings and communications of the parties relating to the subject matter hereof, whether oral or written, with respect thereto. The Company specifically acknowledges and agrees that it is not relying on any oral representation

from Holder or any of its agents. The Company agrees to execute and deliver to Holder such other and further documentation and to undertake such further actions as Holder shall deem necessary to effectuate the provisions of this Agreement. The

Company acknowledges and agrees that each of the Recitals is true and correct in all respects and incorporated herein by reference, as though fully set forth herein.

(n) Reviewed by Attorneys. The Company represents and warrants to Holder that it (a) understands fully the terms of this Agreement and the consequences of the execution and delivery of this Agreement, (b) has been afforded an

opportunity to discuss this Agreement with, and have this Agreement reviewed by, such attorneys and other persons as the Company may wish, and (c) has entered into this Agreement and executed and delivered all documents in connection herewith of

its own free will and accord and without threat, duress or other coercion of any kind by any Person. The parties hereto acknowledge and agree that neither this Agreement nor the other documents executed pursuant hereto will be construed more

favorably in favor of one than the other based upon which party drafted the same, it being acknowledged that all parties hereto contributed substantially to the negotiation and preparation of this Agreement and the other documents executed pursuant

hereto or in connection herewith.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this

Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.

COMPANY:

PDS BIOTECHNOLOGY CORPORATION

By:

/s/ Frank Bedu-Addo

Name:

Frank Bedu-Addo

Title:

Chief Executive Officer

HOLDER:

YA II PN, LTD.

By:

Yorkville Advisors Global, LP

Its:

Investment Manager

By: Yorkville Advisors Global II, LLC

Its: General Partner

By:

/s/ Matt Beckman

Name:

Matt Beckman

Title:

Member

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

Aug. 31, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 31, 2026

Entity File Number

001-37568

Entity Registrant Name

PDS BIOTECHNOLOGY CORPORATION

Entity Central Index Key

0001472091

Entity Incorporation, State or Country Code

Entity Tax Identification Number

26-4231384

Entity Address, Address Line One

303A College Road East

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Postal Zip Code

08540

City Area Code

800

Local Phone Number

208-3343

Title of 12(b) Security

Common Stock, par value $0.00033 per share

Trading Symbol

PDSB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration